GlobalData, the market analysis specialist, has released its new report, “”. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines industry . The report identifies the major industry developments shaping and driving the global Hepatitis A Preventive Vaccines industry . The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the industry positioning of the current industry leaders. Most importantly, the report provides valuable insights on the new product development within the global Hepatitis A Preventive Vaccines segment . This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Industry expert's team of market experts.
GlobalData estimated the global hepatitis A preventive vaccines industry to be worth USD 476m in 2010, and it is projection to grow at 6.2% annually for the next seven years to reach USD 726m by 2017. This medium growth is primarily attributed to growth in vaccination coverage due to increase in recommendation for hepatitis A vaccination. The growth is further supported by increase in tourist traffic globally as hepatitis A vaccines are used as traveler vaccines by tourists. However, supply issues with some vaccines acts as a barrier to the industry .
Scope of the Research
The report provides data on the key drivers and challenges of the Hepatitis A Preventive Vaccines industry . Its Scope of the Research includes -
- Annualized seven key industry s (US, France, Germany, Italy, Spain, UK and Japan) Hepatitis A Preventive Vaccines industry revenues data 2005-2010, projection for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key industry s. Pipeline candidates are very few in number and are majorly product extension of an already approved vaccines. They fall under major vaccine class inactivated vaccine. Analysis of the current and future competition in the seven key countries Hepatitis A Preventive Vaccines industry . Key industry players covered are Merck and Co., GlaxoSmithKline, Sanofi Pasteur MSD and Variation Biotechnologies.
- Insightful review of the key market drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, industry characterization, unmet needs and the implications for the Hepatitis A Preventive Vaccines therapeutics industry .
Why Should You Get This Report?
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of new product development and technologies and by identifying the industry players with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Hepatitis A Preventive Vaccines industry .
- Drive revenues by understanding the major industry developments, innovative products and technologies, industry sectors and industry players likely to impact the global Hepatitis A Preventive Vaccines industry in future.
- Formulate effective sales and industry ing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and industry ing efforts by identifying the industry categories and sectors that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Hepatitis A Preventive Vaccines industry landscape? – Identify, understand and decide.
Drug And Medication Industry in the United Kingdom
1 Table of contents 2
I. 1 List of Data tables 4
I. 2 List of Charts 5
II Hepatitis A preventive Vaccines: Introduction 6
II. 1 Disease Data of Hepatitis A 6
II. 2 Etiology of Hepatitis A 6
II. 3 Risk Factors of Hepatitis A 6
II. 4 Pathopysiology of Hepatitis A 7
II. 5 Symptoms of Hepatitis A 7
II. 6 Epidemiology of Hepatitis A 8
II. 7 Diagnosis of Hepatitis A 8
II. 8 Treatment and Management Pattern of Hepatitis A 8
II. 9 GlobalData Pipeline Report Guidance 9
III Hepatitis A Preventive Vaccines : March ket Characterization 10
III. 1 Hepatitis A Preventive Vaccines, World March ket Size 10
III. 2 Hepatitis A Preventive Vaccines March ket Forecasted data and Compound Annual Growth Rate 11
III. 3 Hepatitis A Preventive Vaccines March ket – The US (2005-2010) 12
III. 4 Hepatitis A Preventive Vaccines March ket Forecasted data – The US (2010-2017) 13
III. 5 Hepatitis A Preventive Vaccines March ket – The UK (2005-2010) 14
III. 6 Hepatitis A Preventive Vaccines March ket Forecasted data – The UK (2010-2017) 15
III. 7 Hepatitis A Preventive Vaccines March ket – Germany (2005-2010) 16
III. 8 Hepatitis A Preventive Vaccines March ket Forecasted data – Germany (2010-2017) 17
III. 9 Hepatitis A Preventive Vaccines March ket – France (2005-2010) 18
III. 10 Hepatitis A Preventive Vaccines March ket Forecasted data – France (2010-2017) 19
III. 11 Hepatitis A Preventive Vaccines March ket – Spain (2005-2010) 20
III. 12 Hepatitis A Preventive Vaccines March ket Forecasted data – Spain (2010-2017) 21
III. 13 Hepatitis A Preventive Vaccines March ket – Italy (2005-2010) 22
III. 14 Hepatitis A Preventive Vaccines March ket Forecasted data – Italy (2010-2017) 23
III. 15 Hepatitis A Preventive Vaccines March ket – Japan (2005-2010) 24
III. 16 Hepatitis A Preventive Vaccines March ket Forecasted data – Japan (2010-2017) 25
III. 17 Drivers and Barriers for the MRSA March ket 26
III. 17.1 Hepatitis A Preventive Vaccines March ket Drivers 26
III. 17.2 Hepatitis A Preventive Vaccines March ket Barriers 26
III. 18 Opportunity and Unmet Need 27
III. 19 Key Takeaway 27
IV Hepatitis A Preventive Vaccines: Competitive Assessment 28
IV. 1 Overview 28
IV. 2 Strategic Competitor Assessment 28
IV. 3 Product Profile for the Major March keted Products in the Hepatitis A preventive Vaccines March ket 29
IV. 3.1 Twinrix 29
IV. 3.2 Havrix 30
IV. 3.3 Vaqta 31
IV. 3.4 Ambirix 32
IV. 3.5 Avaxim 34
IV. 4 Key Takeaway 35
V Hepatitis A Preventive Vaccines: Pipeline Assessment 36
V. 1 Overview 36
V. 2 Strategic Pipeline Assessment 36
V. 3 Hepatitis A Preventive Vaccines – Pipeline analysis by Phases of Development 36
V. 3.1 Hepatitis A Preventive Vaccines – Phase III Pipeline 36
V. 3.2 Hepatitis A Preventive Vaccines – Preclinical Pipeline 37
V. 4 Hepatitis A Preventive Vaccines – Pipeline by Mechanism of Action 37
V. 5 Technology Trends Analytical Framework 38
V. 6 Hepatitis A Preventive Vaccines – Promising Vaccines Under Clinical Development 39
V. 7 Most Promising Vaccine Profiles 39
V. 7.1 Oral Hep A 39
V. 8 Key Takeaway 39
VI Hepatitis A Preventive Vaccine: Clinical Trials Mapping 40
VI. 1 Clinical Trials by Region/Country (US, EU5 & Japan) 40
VI. 2 Clinical Trials by Phase of Clinical Development 41
VI. 3 Clinical Trials by Trial Status 42
VI. 4 Key Sponsors 42
VI. 5 Brief Profiles of Top Ten Firms Participating in Preventive Vaccines Clinical Trials 42
VII Hepatitis A Preventive Vaccines: Strategic Assessment 43
VII. 1 Key Events Impacting the Future March ket 43
VII. 1.1 Hepatitis A Preventive Vaccines: Implications for Future March ket Competition 44
VIII Hepatitis A Preventive Vaccines: Future Players 45
VIII. 1 Introduction 45
VIII. 2 Firms Profiles 46
VIII. 2.1 Merck & Co 46
VIII. 2.2 GlaxoSmithKline 50
VIII. 2.3 Sanofi Pasteur MSD 55
VIII. 2.4 Variation Biotechnologies 55
VIII. 3 Key Takeaway 56
IX Hepatitis A Preventive Vaccines: Appendix 57
IX. 1 Definition 57
IX. 2 Acronyms 57
IX. 3 Research Methodology 57
IX. 3.1 Coverage 57
IX. 3.2 Secondary Research 58
IX. 3.3 Forecasted data ing 58
IX. 3.4 Primary Research 61
IX. 3.5 Expert Panel Validation 61
IX. 4 Contact Us 61
IX. 5 Disclaimer 61
IX. 6 Bibliography 62
1.1 List of Data tables
Data table 1: Hepatitis A Preventive Vaccines March ket, Global, Sales (USD Million), 2005–2010 10
Data table 2: Hepatitis A Preventive Vaccines, Major March ket, Global, Forecasted data s (USD Million), 2010–2017 11
Data table 3: Hepatitis A Preventive Vaccines, The US, Sales (USD Million), 2005–2010 12
Data table 4: Hepatitis A Preventive Vaccines March ket, The US, Forecasted data s (USD Million), 2010–2017 13
Data table 5: Hepatitis A Preventive Vaccines March ket, The UK, Forecasted data s (USD Million), 2010–2017 15
Data table 6: Hepatitis A Preventive Vaccines, Germany, Sales (USD Million), 2005–2010 16
Data table 7: Hepatitis A Preventive Vaccines March ket, Germany, Forecasted data s (USD Million), 2010–2017 17
Data table 8: Hepatitis A Preventive Vaccines, France, Sales (USD Million), 2005–2010 18
Data table 9: Hepatitis A Preventive Vaccines March ket, France, Forecasted data s (USD Million), 2010–2017 19
Data table 10: Hepatitis A Preventive Vaccines, Spain, Sales (USD Million), 2005–2010 20
Data table 11: Hepatitis A Preventive Vaccines March ket, Spain, Forecasted data s (USD Million), 2010–2017 21
Data table 12: Hepatitis A Preventive Vaccines, Italy, Sales (USD Million), 2005–2010 22
Data table 13: Hepatitis A Preventive Vaccines March ket, Italy, Forecasted data s (USD Million), 2010–2017 23
Data table 14: Hepatitis A Preventive Vaccines, Japan, Sales (USD Million), 2005–2010 24
Data table 15: Hepatitis A Preventive Vaccines March ket, Japan, Forecasted data s (USD Million), 2010–2017 25
Data table 16:Havrix Trial Data 30
Data table 17:Hepatitis A – Major Vaccines Dosing Schedule 34
Data table 18: Major March ket Products Comparison in Hepatitis A Preventive Vaccines March ket, 2010 34
Data table 19: Hepatitis A Preventive Vaccines, Phase III Pipeline, 2010 36
Data table 20: Hepatitis A Preventive Vaccines, Preclinical Pipeline, 2010 37
Data table 21: Hepatitis A Preventive Vaccines – Most Promising Vaccines Under Development, 2010 39
Data table 22: Hepatitis A Preventive Vaccines – Clinical Trials by Country, 2010 40
Data table 23: Hepatitis A Preventive Vaccines, Major March kets – Clinical Trials by Phase, 2010 41
Data table 24: Hepatitis A Preventive Vaccines, Major March kets, Clinical Trials by Development Status, 2010 42
Data table 25: Hepatitis A Preventive Vaccines, Major March kets, Key Sponsors, 2010 42
Data table 26: Hepatitis A Preventive Vaccines, Major March kets, Clinical Trials of Top Firms by Phase, 2010 42
Data table 27: Merck & Co. Deals, Alliances and Partner agreements 48
Data table 28: Merck & Co – Hepatitis A March keted Products, 2010 50
Data table 29: GlaxoSmithKline Deals, Alliances and Partner agreements 51
Data table 30:GalaxoSmithKline March keted Products, 2010 54
Data table 31: Sanofi Pasteur MSD March keted Products, 2010 55
Data table 32: Variation Biotechnologies Deals, Alliances and partnerships 55
Data table 33: Variation Biotechnologies Pipeline Products, 2010 56
1.2 List of Charts
Chart 1: Hepatitis A – Pathophysiology 7
Chart 2: Hepatitis A Preventive Vaccines March ket, Global, Sales (USD Million), 2005–2010 10
Chart 3: Hepatitis A Preventive Vaccines March ket, Global, Forecasted data (USD Million), 2010–2017 11
Chart 4: Hepatitis A Preventive Vaccines March ket, The US, Sales (USD Million), 2005–2010 12
Chart 5: Hepatitis A Preventive Vaccines March ket, The US, Forecasted data (USD Million), 2010–2017 13
Chart 6: Hepatitis A Preventive Vaccines March ket, The UK, Sales (USD Million), 2005–2010 14
Chart 7: Hepatitis A Preventive Vaccines March ket, The UK, Forecasted data (USD Million), 2010–2017 15
Chart 8: Hepatitis A Preventive Vaccines March ket, Germany, Sales (USD Million), 2005–2010 16
Chart 9: Hepatitis A Preventive Vaccines March ket, Germany, Forecasted data (USD Million), 2010–2017 17
Chart 10: Hepatitis A Preventive Vaccines March ket, France, Sales (USD Million), 2005–2010 18
Chart 11: Hepatitis A Preventive Vaccines March ket, France, Forecasted data (USD Million), 2010–2017 19
Chart 12: Hepatitis A Preventive Vaccines March ket, Spain, Sales (USD Million), 2005–2010 20
Chart 13 Hepatitis A Preventive Vaccines March ket, Spain, Forecasted data (USD Million), 2010–2017 21
Chart 14: Hepatitis A Preventive Vaccines March ket, Italy, Sales (USD Million), 2005–2010 22
Chart 15: Hepatitis A Preventive Vaccines March ket, Italy, Forecasted data (USD Million), 2010–2017 23
Chart 16: Hepatitis A Preventive Vaccines March ket, Japan, Sales (USD Million), 2005–2010 24
Chart 17: Hepatitis A Preventive Vaccines March ket, Japan, Forecasted data (USD Million), 2010–2017 25
Chart 18: Opportunity and Unmet Need in the Hepatitis A Preventive Vaccines March ket 27
Chart 19: Strategic Competitor Assessment, 2010 28
Chart 20: Hepatitis A Preventive Vaccines Pipeline by Phases of Development, 2010 36
Chart 21: Hepatitis A preventive Vaccines March ket – Pipeline by Mechanism of Action, 2010 37
Chart 22: Technology Trends Analytic Framework for the Hepatitis A Preventive Vaccines Pipeline, 2010 38
Chart 23: Technology Trends Analytic Framework of the Hepatitis A Preventive Vaccines Pipeline – Description, 2010 38
Chart 24: Hepatitis A Preventive Vaccines, Global, Clinical Trials by Country, 2010 40
Chart 25: Hepatitis A Preventive Vaccines, Major March kets – Clinical Trials by Phase, 2010 41
Chart 26: Hepatitis A Preventive Vaccines, Major March kets, Clinical Trials by Development Status, 2010 42
Chart 27: Hepatitis A Preventive Vaccines, Key Events Impacting the Future March ket, 2010 43
Chart 28: Hepatitis A Preventive Vaccines, Implications for Future March ket Competition, 2010 44
Chart 29: Hepatitis A preventive Vaccines March ket – Pipeline by Firms, 2010 45
Chart 30: GlobalData March ket Forecasted data ing Model 60
Companies Mentioned
Merck & Co
GlaxoSmithKline
Sanofi Pasteur MSD
Variation Biotechnologies
